Home › Funds › D. E. Shaw & Co › DNLI
D. E. Shaw & Co position in DNLI
DENALI THERAPEUTICS INC · Health Care
Latest position (Q1 2025)78.22K sh
Reported value held$1.06M
Portfolio Weight0.00%
First reportedQ3 2021
Last changeNew
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 45.41K | $2.29M | New |
| Q4 2021 | 7.24K | $323.00K | Reduce |
| Q1 2022 | 6.25K | $201.00K | Reduce |
| Q2 2022 | 86.11K | $2.53M | Add |
| Q4 2022 | 134.43K | $3.74M | New |
| Q1 2023 | 44.34K | $1.02M | Reduce |
| Q1 2024 | 116.27K | $2.39M | New |
| Q2 2024 | 29.72K | $690.12K | Reduce |
| Q1 2025 | 78.22K | $1.06M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding DNLI
- BlackRock Inc 14.03M sh · $360.76M · Q2 2026
- Baillie Gifford & Co 11.96M sh · $307.62M · Q2 2026
- Vanguard Group 13.06M sh · $215.59M · Q4 2025
- Temasek Holdings 7.01M sh · $180.37M · Q2 2026
- Fidelity Management & Research (FMR) 4.54M sh · $116.66M · Q2 2026
- Goldman Sachs Group 4.16M sh · $106.89M · Q2 2026
- Geode Capital Management 3.97M sh · $102.21M · Q2 2026
- UBS Group AG 3.12M sh · $80.26M · Q2 2026
- Norges Bank Investment Management 2.82M sh · $72.65M · Q2 2026
- Capital Research Global Investors 2.57M sh · $65.99M · Q2 2026
- Casdin Capital 2.04M sh · $52.60M · Q2 2026
- Principal Global Investors 1.42M sh · $36.52M · Q2 2026